April 21st 2025
ASCENT-04 data showed sacituzumab govitecan plus pembrolizumab improved progression-free survival in PD-L1+ metastatic triple-negative breast cancer.
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Nevada
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Missouri
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | New Mexico
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Indiana
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
23rd Annual School of Breast Oncology
November 6-8, 2025
Register Now!
Community Practice Connections™: Navigating Early-Stage HR+/HER2‒- Breast Cancer – Clinical Developments and Innovative Treatments
View More
Community Practice Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Medical Crossfire®: Improving Survival in HR-Positive HER2-Negative Metastatic Breast Cancer – Advances in Selective Estrogen Receptor Targeting Therapies
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow
View More
The Inaugural Hawaii Breast Cancer: A Multidisciplinary Case-Based Conference
View More
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
Medical Crossfire®: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2– Breast Cancer
View More
Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Future Directions in the Treatment of Patients With HR+/HER2- Metastatic Breast Cancer
February 5th 2024Virginia Kaklamani, MD, DSc, explains that key unmet needs in HR+/HER2- metastatic breast cancer include overcoming diverse mechanisms of endocrine resistance with genomic profiling and new agents like oral SERDs while managing side effects.
Watch
Management of Adverse Events in Patients With HR+/HER2- Metastatic Breast Cancer
February 5th 2024Virginia Kaklamani, MD, DSc, explains that managing adverse events like fatigue, GI toxicity, and musculoskeletal pain in patients with HR+/HER2- metastatic breast cancer using approaches such as exercise, anti-nausea medication, acupuncture, and supplements is key to meeting the dual treatment goals of prolonging life and maintaining quality of life.
Watch
Management Approaches for HR+/HER2- mBC Based on Metastasis Location and Disease Burden
January 29th 2024Virginia Kaklamani, MD, DSc, details that disease burden and location of metastases in patients with HR+/HER2- metastatic breast cancer guide approaches to management, with visceral metastases indicating potentially faster progression and more concerning symptoms.
Watch
Review of EMERALD Subgroup Analysis Data From SABCS 2023
January 22nd 2024Subgroup analyses from the EMERALD trial show that oral SERD elacestrant may outperform standard endocrine therapy in metastatic breast cancer patients with bone or visceral metastases who previously received CDK4/6 inhibitors.
Watch
Unmet Needs in the Treatment of Patients With Metastatic Breast Cancer With Visceral Metastases
January 22nd 2024Virginia Kaklamani, MD, DSc, reviews the presented case of a postmenopausal patient with breast cancer who develops metastases after adjuvant endocrine therapy ends, and explains that later treatment selection is difficult because of endocrine resistance and mutations causing more aggressive disease.
Watch
HER2CLIMB-02: Tucatinib and T-DM1 for Previously Treated HER2+ Metastatic Breast Cancer
January 11th 2024Daniel Stover, MD, and the Oncology Brothers review results from HER2CLIMB-02, a randomized, double-blind phase 3 trial of tucatinib and T-DM1 in patients with previously treated HER2+ metastatic breast cancer.
Watch
Update from KATHERINE on Adjuvant T-DM1 for Residual Invasive HER2+ Early Breast Cancer
January 11th 2024Medical oncologists discuss the recent update from the KATHERINE trial investigating adjuvant T-DM1 (trastuzumab emtansine) following neoadjuvant chemotherapy in patients with residual invasive HER2+ early breast cancer.
Watch
Sub-Analysis from APHINITY on Adjuvant Pertuzumab and Trastuzumab in HER2+ Breast Cancer
January 11th 2024Following SABCS 2023, Daniel Stover, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss the benefit of adjuvant pertuzumab and trastuzumab according to ER and HER2 expression in patients with HER2+ breast cancer.
Watch
Kaklamani Discusses Approach to CDK4/6 Inhibitor and Later Therapy for ER+ Breast Cancer
January 11th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Virginia Kaklamani, MD, discussed with participants the case of a patient with estrogen receptor–positive breast cancer who showed signed of progression 20 months after treatment with letrozole plus palbociclib.
Read More
TROPION-Breast01: DatoDXd in Previously Treated Inoperable/Metastatic HR+/HER2- Breast Cancer
January 8th 2024Medical oncologists discuss results from the TROPION-Breast01 study investigating Dato-DXd (datopotamab deurxtecan) in patients with previously treated inoperable or metastatic HR+/HER2- breast cancer.
Watch
Results from INAVO120 in PIK3CA-Mutated HR+/HER2- Locally Advanced/Metastatic Breast Cancer
January 8th 2024Hope Rugo, MD, and the Oncology Brothers review results from the INAVO120 trial studying inavolisib in combination with palbociclib and fulvestrant in PIK3CA-mutated HR+/HER2- locally advanced or metastatic breast cancer.
Watch
MONARCH 3: First-Line Abemaciclib Plus Nonsteroidal AI for HR+/HER2- Advanced Breast Cancer
January 8th 2024Experts on breast cancer review the final overall survival results from MONARCH 3 investigating abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+/HER2- advanced breast cancer.
Watch
Final iDFS Analysis from NATALEE in HR+/HER2- Early Breast Cancer
January 8th 2024Following SABCS 2023, Hope Rugo, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss the final invasive disease-free survival analysis from the NATALEE trial in HR+/HER2- early breast cancer.
Watch
ADC Choices Require Discretion in HER2-Negative MBC
January 4th 2024As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.
Read More